Soleno Therapeutics, Inc.
(NASDAQ : SLNO)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Medical Specialties
symbolcompany%chnglast%shortavg$volume
DXCMDexCom, Inc. 5.70%364.498.2%$1010.73m
ABTAbbott Laboratories 1.85%89.880.8%$687.47m
MDTMedtronic Plc 5.18%102.010.6%$656.19m
BDXBecton, Dickinson & Co. -0.68%241.891.0%$647.52m
DHRDanaher Corp. 2.61%173.190.7%$645.19m
TMOThermo Fisher Scientific, Inc. 1.72%354.131.0%$503.14m
BSXBoston Scientific Corp. 3.77%38.831.0%$437.50m
ISRGIntuitive Surgical, Inc. 5.05%592.762.4%$398.72m
SYKStryker Corp. 4.48%206.951.3%$354.31m
INOInovio Pharmaceuticals, Inc. 0.42%11.936.3%$337.96m
ALGNAlign Technology, Inc. 10.82%288.216.4%$324.61m
WSTWest Pharmaceutical Services, Inc. 0.16%205.721.6%$293.42m
BAXBaxter International, Inc. 0.60%89.161.8%$247.08m
ZBHZimmer Biomet Holdings, Inc. 6.12%137.441.7%$203.62m
QDELQuidel Corp. -2.07%153.647.7%$202.30m

Company Profile

Soleno Therapeutics, Inc. engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. The company focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.